Back to today’s briefing

Story perspectives

Opioid Overdose Deaths Drop, New Treatments Offer Hope

1/29/2025

41 8

Summary

Story summary

The CDC reports a 12% decline in opioid overdose deaths in 2022, yet synthetic fentanyl remains a major threat.
Vertex Pharmaceuticals aims for approval of suzetrigine, a non-opioid treatment that may transform acute pain management.
Protega Pharmaceuticals introduces Roxybond, an abuse-deterrent opioid designed to enhance safety in pain management.
Increased government scrutiny is making it harder for patients to access necessary pain medications.

1 of 1

Story summary

The CDC reports a 12% decline in opioid overdose deaths in 2022, yet synthetic fentanyl remains a major threat.
Vertex Pharmaceuticals aims for approval of suzetrigine, a non-opioid treatment that may transform acute pain management.
Protega Pharmaceuticals introduces Roxybond, an abuse-deterrent opioid designed to enhance safety in pain management.
Increased government scrutiny is making it harder for patients to access necessary pain medications.